BIO-RAD LABORATORIES INC
For the period ended Dec 31, 2024. Filed Feb 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 14, 2025
BIO$386.48-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at
Consolidated Balance Sheets
(In millions, except share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $488.1 | $403.8 |
| Short-term investments | 1,176.4 | 1,203.3 |
| Restricted investments | — | 5.6 |
| Accounts receivable, less allowance for credit losses of $9.2 and $14.9 as of December 31, 2024 and 2023, respectively | 452.5 | 489.0 |
| Inventory | 760.0 | 780.5 |
| Prepaid expenses | 122.6 | 140.0 |
| Other current assets | 30.7 | 26.1 |
| Total current assets | 3,030.3 | 3,048.3 |
| Property, plant and equipment, net | 528.1 | 529.0 |
| Operating lease right-of-use assets | 160.5 | 194.7 |
| Goodwill, net | 410.5 | 413.6 |
| Purchased intangibles, net | 293.6 | 320.5 |
| Other investments | 4,839.2 | 7,698.1 |
| Other assets | 101.9 | 94.9 |
| Total assets | $9,364.1 | $12,299.1 |
Consolidated Balance Sheets
(continued)
(In millions, except share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $122.3 | $144.6 |
| Accrued payroll and employee benefits | 124.2 | 139.9 |
| Current maturities of long-term debt and notes payable | 1.2 | 0.5 |
| Income and other taxes payable | 31.2 | 35.8 |
| Current operating lease liabilities | 41.7 | 40.4 |
| Other current liabilities | 147.2 | 161.6 |
| Total current liabilities | 467.8 | 522.8 |
| Long-term debt, net of current maturities | 1,200.4 | 1,199.1 |
| Deferred income taxes | 818.0 | 1,475.5 |
| Operating lease liabilities | 131.4 | 165.5 |
| Other long-term liabilities | 177.2 | 195.0 |
| Total liabilities | 2,794.8 | 3,557.9 |
| Commitments and contingent liabilities | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none | — | — |
| Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 25,191,463 and 25,169,944 at 2024 and 2023, respectively; shares outstanding - 22,936,735 and 23,422,506 at 2024 and 2023, respectively | — | — |
| Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued and outstanding - 5,074,409 and 5,095,930 at 2024 and 2023, respectively | — | — |
| Additional paid-in capital | 463.2 | 449.1 |
| Class A treasury stock at cost, 2,254,728 shares at 2024 and 1,747,438 shares at 2023 | (772.1) | (632.5) |
| Retained earnings | 7,416.4 | 9,260.6 |
| Accumulated other comprehensive loss | (538.2) | (336.0) |
| Total stockholders’ equity | 6,569.3 | 8,741.2 |
| Total liabilities and stockholders’ equity | $9,364.1 | $12,299.1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.